PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.08%
G&A change of 6.08% while AXSM maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
0.73%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
5.73%
Similar operating expenses growth to AXSM's 6.62%. Walter Schloss would investigate norms.
5.73%
Total costs growth 50-75% of AXSM's 8.31%. Bruce Berkowitz would examine efficiency.
3.59%
Interest expense growth less than half of AXSM's 24.56%. David Dodd would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
-5.73%
EBITDA decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-5.73%
Operating income decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.82%
Tax expense change of 4.82% while AXSM maintains burden. Bruce Berkowitz would investigate strategy.
-4.82%
Net income decline while AXSM shows 19.26% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-5.05%
EPS decline while AXSM shows 20.49% growth. Joel Greenblatt would examine position.
-5.05%
Diluted EPS decline while AXSM shows 20.49% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.